OCULIS HOLDING AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.64 USD | -0.55% |
|
-3.29% | +12.56% |
| Apr. 24 | H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating | MT |
| Apr. 24 | Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 914K 1.01M | Sales 2025 * | 10.9M 12M | Capitalization | 477M 526M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -63.85M | Net income 2025 * | -72M -79.26M | EV / Sales 2024 * | 435 x |
| Net cash position 2024 * | 79.97M 88.03M | Net cash position 2025 * | 25.15M 27.68M | EV / Sales 2025 * | 41.5 x |
| P/E ratio 2024 * |
-7.41
x | P/E ratio 2025 * |
-6.42
x | Employees | 36 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.76% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.55% | ||
| 1 week | -3.29% | ||
| Current month | -3.29% | ||
| 1 month | +13.26% | ||
| 3 months | -0.08% | ||
| 6 months | +30.18% | ||
| Current year | +12.56% |
1 week
12.36
13.07
1 month
10.7113.30
Current year
10.1114.47
1 year
9.0514.50
3 years
6.2614.50
5 years
6.2614.50
10 years
6.2614.50
| Managers | Title | Age | Since |
|---|---|---|---|
Riad Sherif
CEO | Chief Executive Officer | 56 | 17-11-30 |
Sylvia Cheung
DFI | Director of Finance/CFO | 50 | 20-08-31 |
Ramin Tadayoni
CTO | Chief Tech/Sci/R&D Officer | 54 | Feb. 27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 18-03-31 | |
| Director/Board Member | 69 | 23-03-02 | |
| Director/Board Member | 58 | 23-03-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 12.37 | -2.14% | 43,046 |
| 24-05-07 | 12.64 | -0.55% | 10,996 |
| 24-05-06 | 12.71 | -0.70% | 27,049 |
| 24-05-03 | 12.8 | -0.93% | 28,510 |
| 24-05-02 | 12.92 | +0.54% | 42,885 |
End-of-day quote Nasdaq, May 06, 2024
More quotes
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Calendar
2024-05-08
- Retina World Congress
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.23
CHF
Average target price
25.49
CHF
Spread / Average Target
+126.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.56% | 526M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- OCS Stock